David Hung, Nuvation Bio CEO
August 5, 2024 03:35 PM EDT
R&D

Nu­va­tion paus­es BET in­hibitor plans af­ter check­ing out in­ter­im Phase 1 da­ta

Max Bayer

Pharma Reporter

Nu­va­tion Bio won’t take its can­cer drug NUV-868 in­to a Phase 2 tri­al for now, fol­low­ing a look at in­ter­im safe­ty and ef­fi­ca­cy da­ta from …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times